The company has over $90+ million of shareholder cash tied up in depreciating inventory. They were obligated to order $30 million in 2020 and anticipated a BLA approval and follow on launch. That clearly didn't happen and now they face inventory aging issues as many wholesalers won't accept short dated inventory. As HIV combo approvals are late into 2022, there is likely to be more write offs.
Market Data 
Markets 
AI
